Vitamin K1 and progression of cardiovascular calcifications in hemodialysis patients: the VitaVasK randomized controlled trial

Saritas T, Reinartz S, Krueger T, Ketteler M, Liangos O, Labriola L, Stenvinkel P, Kopp C, Westenfeld R, Evenepoel P, Siepmann R, Wied S, Hilgers RD, Schurgers L, Floege J (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Clinical Kidney Journal Oxford University Press

DOI: 10.1093/ckj/sfac184

Abstract

Lay Summary Patients on chronic dialysis exhibit extensive cardiovascular calcifications and vitamin K deficiency. The vitamin K-dependent matrix Gla protein (MGP) is a potent inhibitor of vascular calcification. The multicentre, randomized, open-label, controlled VitaVasK trial showed marked attenuation of cardiovascular calcification progression in chronic haemodialysis patients treated with vitamin K1. Vitamin K1 supplementation greatly increased the serum vitamin K concentration and reduced inactive MGP levels. The treatment was safe, as no adverse advents were noted. Larger randomized controlled trials are needed to confirm vitamin K1 therapy as a safe, potent and cost-effective treatment option to reduce the progression of vascular calcification in haemodialysis patients.

Authors with CRIS profile

Christoph Kopp Department of Medicine 4 – Nephrology and Hypertension

Involved external institutions

University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven BE Belgium (BE) Universitätsklinikum Aachen (UKA) DE Germany (DE) Karolinska University Hospital / Karolinska Universitetssjukhuset SE Sweden (SE) Maastricht University NL Netherlands (NL) Université Catholique de Louvain (UCL) BE Belgium (BE) Heinrich-Heine-Universität Düsseldorf DE Germany (DE) KfH Kuratorium für Dialyse und Nierentransplantation e.V. DE Germany (DE) Robert-Bosch-Krankenhaus DE Germany (DE)

How to cite

APA:

Saritas, T., Reinartz, S., Krueger, T., Ketteler, M., Liangos, O., Labriola, L.,... Floege, J. (2022). Vitamin K1 and progression of cardiovascular calcifications in hemodialysis patients: the VitaVasK randomized controlled trial. Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfac184

MLA:

Saritas, Turgay, et al. "Vitamin K1 and progression of cardiovascular calcifications in hemodialysis patients: the VitaVasK randomized controlled trial." Clinical Kidney Journal (2022).

BibTeX: Download